Prafull Ghatage

9.5k total citations
110 papers, 2.9k citations indexed

About

Prafull Ghatage is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Prafull Ghatage has authored 110 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Reproductive Medicine, 36 papers in Oncology and 35 papers in Obstetrics and Gynecology. Recurrent topics in Prafull Ghatage's work include Ovarian cancer diagnosis and treatment (50 papers), Endometrial and Cervical Cancer Treatments (34 papers) and Cervical Cancer and HPV Research (12 papers). Prafull Ghatage is often cited by papers focused on Ovarian cancer diagnosis and treatment (50 papers), Endometrial and Cervical Cancer Treatments (34 papers) and Cervical Cancer and HPV Research (12 papers). Prafull Ghatage collaborates with scholars based in Canada, United States and Spain. Prafull Ghatage's co-authors include Martin Köbel, Nilanchali Singh, Amit M. Oza, Jill Nation, Gregg Nelson, Corinne Doll, Laurie Elit, Pamela Chu, Susan P. Lees‐Miller and Diane Provencher and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Prafull Ghatage

108 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prafull Ghatage Canada 29 1.3k 887 855 845 687 110 2.9k
Masoud Azodi United States 32 1.2k 0.9× 1.0k 1.2× 1.4k 1.6× 809 1.0× 531 0.8× 162 3.3k
Satoru Sagae Japan 28 1.3k 1.0× 982 1.1× 731 0.9× 900 1.1× 529 0.8× 75 3.0k
Mariusz Bidziński Poland 24 998 0.8× 687 0.8× 838 1.0× 536 0.6× 454 0.7× 142 2.2k
Ronald P. Zweemer Netherlands 27 1.6k 1.2× 1.1k 1.3× 703 0.8× 438 0.5× 508 0.7× 109 2.9k
Raji Ganesan United Kingdom 30 1.2k 0.9× 1.6k 1.8× 428 0.5× 547 0.6× 715 1.0× 112 3.1k
Catherine Lhommé France 33 2.0k 1.5× 1.0k 1.2× 949 1.1× 1.3k 1.5× 955 1.4× 119 4.2k
Debra A. Bell United States 33 2.0k 1.6× 868 1.0× 666 0.8× 668 0.8× 639 0.9× 80 3.3k
Natália Buza United States 33 689 0.5× 870 1.0× 1.2k 1.4× 673 0.8× 349 0.5× 134 2.9k
Heather A. Lankes United States 30 1.4k 1.1× 948 1.1× 1.3k 1.5× 931 1.1× 276 0.4× 91 3.3k
J. Kærn Norway 36 2.3k 1.8× 1.2k 1.4× 809 0.9× 640 0.8× 1.1k 1.6× 111 3.5k

Countries citing papers authored by Prafull Ghatage

Since Specialization
Citations

This map shows the geographic impact of Prafull Ghatage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prafull Ghatage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prafull Ghatage more than expected).

Fields of papers citing papers by Prafull Ghatage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prafull Ghatage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prafull Ghatage. The network helps show where Prafull Ghatage may publish in the future.

Co-authorship network of co-authors of Prafull Ghatage

This figure shows the co-authorship network connecting the top 25 collaborators of Prafull Ghatage. A scholar is included among the top collaborators of Prafull Ghatage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prafull Ghatage. Prafull Ghatage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lheureux, Stéphanie, Taymaa May, Michelle Wilson, et al.. (2024). Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.. Journal of Clinical Oncology. 42(16_suppl). 5506–5506. 1 indexed citations
2.
3.
4.
Dorigo, Oliver, Amit M. Oza, Tanja Pejović, et al.. (2023). Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial. Clinical Cancer Research. 29(15). 2808–2815. 7 indexed citations
5.
Kang, Eun Young, Tatjana Terzić, Prafull Ghatage, et al.. (2023). TP53 as a Diagnostic Aid in the Distinction of Ovarian Mucinous Borderline Tumors From Mucinous Carcinoma. International Journal of Gynecological Pathology. 43(2). 111–122. 4 indexed citations
6.
Oaknin, Ana, Lucy Gilbert, Anna V. Tinker, et al.. (2023). A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. 19(25). 1709–1714. 1 indexed citations
7.
Martell, Kevin, John B. McIntyre, Tasnima Abedin, et al.. (2023). Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery. International Journal of Gynecological Pathology. 43(2). 158–170. 1 indexed citations
8.
Martell, Kevin, Tien Phan, Robyn Banerjee, et al.. (2023). Impact of Immune, Inflammatory, and Nutritional Indices on Outcome in Patients with Cervical Cancer Treated with Definitive (Chemo)radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e513–e513. 1 indexed citations
9.
Köbel, Martin, Eunyoung Kang, Sandra Lee, et al.. (2023). Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma. Histopathology. 84(7). 1095–1110. 6 indexed citations
10.
Vermij, Lisa, Jan J. Jobsen, Mariël Brinkhuis, et al.. (2022). 2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers. International Journal of Gynecological Cancer. 32. A97–A98. 1 indexed citations
11.
Singh, Nilanchali, et al.. (2022). Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective. Cancer Control. 29. 2905537397–2905537397. 3 indexed citations
12.
Singh, Nilanchali, et al.. (2021). Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Cureus. 13(6). e15563–e15563. 16 indexed citations
13.
Singh, Nilanchali, et al.. (2021). Sexual Dysfunction in Cervical Cancer Survivors: A Scoping Review. Women s Health Reports. 2(1). 594–607. 17 indexed citations
14.
Wiedemeyer, Katharina, Linyuan Wang, Eun Young Kang, et al.. (2021). Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology. 41(2). 168–179. 9 indexed citations
15.
Brett, Mary Anne, Eshetu G. Atenafu, Nilanchali Singh, et al.. (2020). Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. International Journal of Gynecological Pathology. 40(2). 116–123. 51 indexed citations
16.
Bisch, Steven, Sarah Glaze, A. T. Cameron, et al.. (2019). Impact of transversus abdominis plane blocks versus non-steroidal anti-inflammatory on post-operative opioid use in ERAS ovarian cancer surgery. International Journal of Gynecological Cancer. 29(9). 1372–1376. 10 indexed citations
17.
Bisch, Steven, Tiffany Wells, Leah Gramlich, et al.. (2018). Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes. Gynecologic Oncology. 151(1). 117–123. 105 indexed citations
18.
Enwere, Emeka K., Elizabeth Kornaga, Michelle L. Dean, et al.. (2017). Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Modern Pathology. 30(4). 577–586. 145 indexed citations
19.
McIntyre, John B., Gregg Nelson, Prafull Ghatage, et al.. (2013). PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. Gynecologic Oncology. 132(1). 188–193. 21 indexed citations
20.
Oza, Amit M., Elizabeth A. Eisenhauer, Laurie Elit, et al.. (2008). Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. Journal of Clinical Oncology. 26(26). 4319–4325. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masoud Azodi Breakdown of academic impact, for papers by Satoru Sagae Breakdown of academic impact, for papers by Mariusz Bidziński Breakdown of academic impact, for papers by Ronald P. Zweemer Breakdown of academic impact, for papers by Raji Ganesan Breakdown of academic impact, for papers by Catherine Lhommé Breakdown of academic impact, for papers by Debra A. Bell Breakdown of academic impact, for papers by Natália Buza Breakdown of academic impact, for papers by Heather A. Lankes Breakdown of academic impact, for papers by J. Kærn
Rankless by CCL
2026